|
|
|
|
Drugs and Medicines Used in Disorders of The Heart
Diltiazem (Dilzem 30 mg, Dilzem SR 90 mg) Its action on the heart rate is less than verapamil.It decreases blood pressure to a lesser extent than nifedipine. It relieves spasms of coronary arteries. It is also useful in PAT (Paoxysmal...
|
|
|
Sucampo to Host Third Quarter 2008 Financial Results Conference Call on November 12, 2008
- Sucampo Pharmaceuticals, Inc.(NASDAQ:SCMP) today announced that it will sponsor a conference call to discuss its financial results for the quarter ended September 30, 2008. These results are expected to be disclosed on Wednesday,...
|
|
|
Current Perspectives in IBS and Chronic Constipation: An Expert Interview With Brian E. Lacy, MD, PhD
_ Current Perspectives in IBS and Chronic Constipation: An Expert Interview With Brian E.Lacy, MD, PhD.
|
|
|
Further Characterization of Painful Constipation (PC): Clinical Features Over One Year and Comparison With IBS
_ Further Characterization of Painful Constipation (PC): Clinical Features Over One Year and Comparison With IBS.
|
|
|
ASCP's E-IMPACCT Initiative Helps Health Care Practitioners Better Manage Chronic Constipation in Older Adults
ALEXANDRIA, Va., Oct.23 /PRNewswire-USNewswire/ -- The American Society of Consultant Pharmacists (ASCP) has launched a comprehensive continuing medical education initiative for physicians, nurses, pharmacists, and other health care...
|
|
|
Prucalopride Significantly Improves Symptoms in Chronic Constipation: Presented at UEGW
-- In patients with severe chronic constipation, the new enterokinetic agent prucalopride increases the rates of bowel movements without a rebound effect, according to a study presented here at the 16th United European Gastroenterology Week ...
|
|
|
Prucalopride Significantly Improves Symptoms in Chronic Constipation: Presented at UEGW
-- In patients with severe chronic constipation, the new enterokinetic agent prucalopride increases the rates of bowel movements without a rebound effect, according to a study presented here at the 16th United European Gastroenterology Week ...
|
|
|
ASCP's E-IMPACCT Initiative Helps Health Care Practitioners Better Manage Chronic Constipation in Older Adults
/PRNewswire-USNewswire/ -- The American Society of Consultant Pharmacists (ASCP) has launched a comprehensive continuing medical education initiative for physicians, nurses, pharmacists, and other health care providers about chronic...
|
|
|
Sucampo Europe Presents Long-Term Safety and Efficacy Data of Lubiprostone in Chronic Idiopathic Constipation
Sucampo Pharma Europe, Ltd., a wholly-owned subsidiary of Sucampo Pharmaceuticals, Inc.(NASDAQ: SCMP), today announced the results from three open-labeled, long-term (6 and 12 months) clinical trials of lubiprostone (AMITIZA(R)). These...
|
|
|
Sucampo Europe Presents Long-Term Safety and Efficacy Data of Lubiprostone in Chronic Idiopathic Constipation
- Sucampo Pharma Europe, Ltd., a wholly-owned subsidiary of Sucampo Pharmaceuticals, Inc.(NASDAQ: SCMP), today announced the results from three open-labeled, long-term (6 and 12 months) clinical trials of lubiprostone (AMITIZA(R)).
|
|
|
Sucampo Europe Presents Long-Term Safety and Efficacy Data of Lubiprostone in Chronic Idiopathic Constipation
- Sucampo Pharma Europe, Ltd., a wholly-owned subsidiary of Sucampo Pharmaceuticals, Inc.(NASDAQ: SCMP), today announced the results from three open-labeled, long-term (6 and 12 months) clinical trials of lubiprostone (AMITIZA). These...
|
|
|
Sucampo Pharma Europe
John Eccles House, Oxford Science Park Robert Robinson Avenue Oxford OX4 4GP United Kingdom Phone: 44-0-18-65-338-440 Fax: 44-0-18-65-338-104 Industry Segment Company News Presents Long-Term Safety and Efficacy Data of Lubiprostone in...
|
|
|
Sucampo Names Stanley G. Miele Head of Sales & Marketing
BETHESDA, MD.--(BUSINESS WIRE)--Oct.16, 2008 - Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) today announced the promotion of Stanley G. Miele to Senior Vice President, Sales & Marketing, effective October 13, 2008. Miele will...
|
|
|
Ono Obtains Japanese License for Progenics' Constipation Therapy for $15M
Ono Pharmaceuticalis paying $15 million for rights to develop Progenics Pharmaceuticals opioid-induced constipation drug, Relistor, in Japan.Progenics stands to earn $20 million in milestones related to the development. Ono is...
|
|
|
Sucampo Names Stanley G. Miele Head of Sales & Marketing
- Sucampo Pharmaceuticals, Inc.(NASDAQ:SCMP) today announced the promotion of Stanley G. Miele to Senior Vice President, Sales & Marketing, effective October 13, 2008. Miele will report directly to Ryuji Ueno, M.D., Ph.D., Ph.D.,...
|
|
|
IBS-C and Chronic Constipation: Clinical Practice Assessment
To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View...
|
|
|
Sucampo Pharmaceuticals Invites Investors to Listen to Webcast of Presentation at UBS Conference
BETHESDA, MD -- (Business Wire) Sucampo Pharmaceuticals, Inc.(NASDAQ:SCMP) today announced that its presentation at the UBS Global Life Sciences Conference will be webcast and may be accessed at www.sucampo.com A member of Sucampo...
|
|
|
Sucampo announces positive phase 2b study of Amitiza
Sucampo Pharmaceuticals, Inc announced results of its phase-2b dose-ranging study of Amitiza (lubiprostone) in patients with Chronic Idiopathic Constipation (CIC), conducted in Japan.The study demonstrated a statistically...
|
|
|
Antipsychotic Drug May Ease Anxiety
Sept.4, 2008 -- Seroquel XR, an antipsychotic drug approved to treat schizophrenia and bipolar disorder, may ease generalized anxiety disorder, new research shows. Seroquel XR (the 'XR' stands for 'extended-release') is approved to...
|
